Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors
Conditions
Interventions
IPG7236
Locations
7
United States
Providence Portland Medical Center
Portland, Oregon, United States
NEXT Oncology
Austin, Texas, United States
The First Affiliated Hospital Nanchang Univeristy
Nanchang, Jiangxi, China
Shandong Cancer Hospital
Jinan, Shangdong, China
Shanghai East Hospital
Shanghai, China
Shanghai General Hospital
Shanghai, China
Start Date
November 15, 2021
Primary Completion Date
September 21, 2025
Completion Date
December 21, 2025
Last Updated
September 24, 2025
NCT07052162
NCT04961593
NCT02456974
NCT06426836
NCT06752122
NCT06859723
Lead Sponsor
Nanjing Immunophage Biotech Co., Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions